Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone

FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions.

"Endoscopic biopsy findings do not always tell the whole story when it comes to a patient's risk of progression," said study author Virendra Joshi, M.D., FAGA, FACG, board-certified gastroenterologist and associate professor in the Division of Digestive Diseases in the Department of Medicine at Emory University School of Medicine in Atlanta. "The studies being presented at ACG demonstrate how TissueCypher can complement standard pathology by providing objective molecular risk information that helps guide surveillance and treatment decisions for patients with Barrett's esophagus, particularly when a patient's molecular risk suggests a different approach than their biopsy diagnosis alone would indicate."

BE is a precancerous condition associated with an increased risk of esophageal adenocarcinoma (EAC), yet biopsy findings alone do not always accurately reflect a patient's individual biological risk of progression. TissueCypher analyzes protein biomarkers and tissue architecture in routine endoscopic biopsy samples to provide an individualized five-year probability of progression to high-grade dysplasia (HGD) or EAC.

Study findings and presentation details are included below. All posters will be presented in Exhibit Halls A-D (Level 3) at Music City Center.

P3056: The Tissue Systems Pathology Test Enabled Detection of Missed Prevalent Dysplasia in a Presumed Clinically Low-Risk Patient With Non-Dysplastic Barrett's Esophagus

- Presenting author: Salih Samo, M.D., University of Kansas School of Medicine

- Date and Time: Monday, Oct. 12; 10:30 a.m.-4:15 p.m. Central time

- Key findings: According to gastroenterology society guidelines, patients diagnosed with non-dysplastic BE (NDBE) are generally recommended to undergo surveillance endoscopy every three to five years because they are considered at relatively low risk of progression. However, biopsy findings alone may not fully reflect a patient's underlying biological risk, and some patients may harbor advanced precancerous changes that cannot be detected through routine histopathologic assessment alone. In this case report, TissueCypher returned a high-risk result for a patient with NDBE, indicating a 62% probability of progression to HGD or EAC within five years. The result informed a risk-based management approach and led to a repeat endoscopy six months after the initial examination, at which previously missed prevalent HGD was identified. The patient subsequently underwent endoscopic eradication therapy (EET) with radiofrequency ablation (RFA). This case illustrates how TissueCypher may help identify elevated risk among patients with an NDBE diagnosis, helping clinicians identify patients who may benefit from earlier evaluation and intervention than would otherwise be recommended based on histology alone.

P5192: Real-World Impact of Tissue Systems Pathology Test on Barrett's Esophagus Management: A Multi-Center Cohort Study

- Presenting author: Shree Patel, M.D., Emory University School of Medicine

- Date and Time: Tuesday, Oct. 13; 10:30 a.m.-4 p.m. Central time

- Key findings: Histopathology and clinical factors alone may not fully identify which patients with BE are at elevated risk of progression to HGD/EAC. In the study, molecular risk stratification using TissueCypher was compared with the Progression in Barrett's (PIB) clinicopathologic-based risk stratification approach. There was only slight agreement between the two approaches (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk, whereas the PIB score classified 31% of patients as low risk and 69% as intermediate/high risk. Following TissueCypher testing, management recommendations were changed in a manner consistent with the test's risk classification for 96% of patients in this cohort, suggesting that the results informed clinical decision-making in this study population. Under guideline-informed management, most patients would have been recommended surveillance every three years using the PIB approach. However, guided by TissueCypher results, physicians recommended a longer five-year surveillance window for 38 patients and EET for eight, which included five patients with NDBE whose TissueCypher results indicated intermediate or high risk or progression despite having no dysplasia detected on their biopsy. These findings suggest that TissueCypher may provide additional risk information beyond clinicopathologic assessment to support more individualized surveillance and treatment recommendations.

P5296: The Tissue Systems Pathology Test Facilitated Early Intervention in a Histopathologically Complex Case of Barrett's Esophagus

- Presenting author: Shree Patel, M.D., Emory University School of Medicine

- Date and Time: Tuesday, Oct. 13; 10:30 a.m.-4 p.m. Central time

- Key findings: Conflicting biopsy results can make it difficult to determine the appropriate management strategy for patients with BE. In this case, a patient's biopsies were successively classified as NDBE, low-grade dysplasia (LGD) and indefinite for dysplasia (IND), creating uncertainty about the patient's risk and management plan. TissueCypher testing of the IND biopsy returned a high-risk result, indicating a 47% probability of progression to HGD or EAC within five years. The high-risk result prompted an interventional endoscopy with RFA two months after the endoscopy that yielded the IND diagnosis. Biopsies obtained during the procedure confirmed previously undetected HGD, consistent with the TissueCypher high-risk classification. Following RFA and subsequent cryotherapy, follow-up biopsies confirmed complete eradication of the patient's intestinal metaplasia. This case illustrates how TissueCypher may help reduce uncertainty for patients with inconclusive or discordant biopsy findings by providing objective risk information that supports timely intervention and individualized patient management.

TissueCypher Product Theater

- Date and Time: Tuesday, Oct. 13; 1:15-1:45 p.m. Central time

- Location: Product Theater Area (Booth 117)

- Castle will host a product theater titled, "Low-risk on histology. High-risk in reality: Johnny Walker's journey with Barrett's esophagus." During the session, TissueCypher patient ambassador Johnny Walker will join Mark Amorosino, M.D., gastroenterologist at Gastro Health, and David Forcione, M.D., advanced endoscopist at Baptist Health, to discuss how TissueCypher's molecular risk assessment provided additional insight beyond his NDBE diagnosis and informed treatment decisions that ultimately led to the detection of dysplasia.

For more information on TissueCypher, visit Castle at Booth 1706.

About TissueCypher Barrett's Esophagus Test

TissueCypher is a precision medicine test designed and extensively validated to predict a patient's personalized risk of progression from Barrett's esophagus (BE) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Indicated for patients with non-dysplastic BE, indefinite for dysplasia or with low-grade dysplasia, TissueCypher's five-year risk assessment is designed to help physicians tailor care to each patient's risk of developing HGD or EAC.

Backed by more than 17 peer-reviewed publications and studied in biopsies from more than 8,000 patients, TissueCypher has been shown to be the strongest independent predictor of progression compared with traditional histopathological risk assessment. Using an AI-derived spatialomics approach, the test identifies molecular signatures that often precede the development of dysplasia, which can enable earlier identification, treatment, and management of patients at increased risk of cancer. TissueCypher is designed to integrate seamlessly into routine endoscopic practice by analyzing standard esophageal pinch biopsies, delivering actionable insights without requiring additional procedures. Learn more at CastleBiosciences.com/TissueCypher.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections.

NEW YORK BLOOD CENTER ENTERPRISES APPOINTS MEGHAN DELANEY, DO, MPH, AS NEXT PRESIDENT & CHIEF EXECUTIVE OFFICER

Current President and CEO Christopher D. Hillyer, MD, to serve as Special Advisor to the Board of Trustees

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- The Board of Trustees of New York Blood Center Enterprises (NYBCe) has appointed Meghan Delaney, DO, MPH, as the organization's next President and Chief Executive Officer following an extensive national search. Dr. Delaney will assume the role on January 4, 2027, succeeding Christopher D. Hillyer, MD, who has led the organization since 2009.

Dr. Hillyer will transition to the role of Special Advisor to NYBCe's Board of Trustees. In this capacity, he will work closely with Dr. Delaney to support a smooth transition while continuing to provide strategic guidance to the Board and NYBCe leadership, ensuring the organization continues to benefit from his experience, expertise, and deep institutional knowledge.

During his 17-year tenure, Dr. Hillyer transformed NYBCe from a regional blood center and research institution into an internationally recognized life sciences enterprise serving 16 states and more than 550 hospitals. Under his leadership, NYBCe expanded the work of its Lindsley F. Kimball Research Institute (LFKRI) and advanced its capabilities in genomics, cellular therapies, and biomanufacturing. Key milestones included the FDA approval of HemaCord, the first FDA-licensed hematopoietic progenitor cell therapy product; the establishment of Comprehensive Cell Solutions; the founding of NYBC Ventures, a $50 million life sciences investment fund; and the opening of NYBCe's new Rye Master Campus, consolidating blood operations, research and cell therapy manufacturing under one roof.

"Dr. Hillyer's extraordinary contributions have left a lasting impact on NYBCe and the patients and communities we serve," said Marc Kramer, Chairman of NYBCe's Board of Trustees. "We are deeply grateful for his dedication and pleased that the organization will continue to benefit from his expertise and guidance. We are equally excited to welcome Dr. Delaney, whose clinical, scientific, and executive experience positions her well to guide NYBCe into the future."

"It has been a distinct honor and privilege to lead NYBCe for the better part of two decades. I am incredibly proud of what we have accomplished together and deeply grateful to the extraordinary people who make this organization what it is today," said Dr. Hillyer. "I look forward to welcoming Dr. Delaney and supporting her success as NYBCe continues to grow, innovate, and advance its lifesaving mission."

Dr. Delaney currently serves as Associate Chief Clinical Officer, Division Chief of Pathology and Laboratory Medicine, and Director of Transfusion Medicine at Children's National in Washington, D.C. She is also a Professor of Pathology and Pediatrics at the George Washington University School of Medicine and Health Sciences and serves on the Board of Directors of the Association for the Advancement of Blood & Biotherapies (AABB).

"I am honored to have been selected as the next President and CEO of New York Blood Center Enterprises and look forward to building on its exceptional history of service, scientific excellence, and innovation," said Dr. Delaney. "NYBCe plays a vital role in patient care, public health, scientific discovery, and the future of blood and cellular therapies. I am excited to work alongside its talented and dedicated employees, partners, and the communities we serve to embrace new opportunities and expand our impact for generations to come."

About New York Blood Center Enterprises (NYBCe)

Founded in 1964, New York Blood Center Enterprises (NYBCe) has provided more than 60 years of lifesaving research, innovation, and impact. NYBCe is one of the largest nonprofit blood centers, operating in 16 states and serving 75 million people. NYBCe operates Blood Bank of Delmarva, Community Blood Center of Greater Kansas City, Connecticut Blood Center, Memorial Blood Centers, Nebraska Community Blood Bank, New Jersey Blood Services, New York Blood Center, and Rhode Island Blood Center, delivering more than one million blood products to nearly 550 U.S. hospitals annually. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic, and biopharmaceutical organizations. NYBCe's Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBCe is a vital community lifeline dedicated to helping patients and advancing global public health. To learn more, visit nybce.org. Connect with us on Facebook, X, Instagram, and LinkedIn.

SOURCE New York Blood Center Enterprises

Share this article

New Poetry Collection Explores Healing After Life's Hardest Moments

"Refine" offers readers an unfiltered look at the resilience of the human spirit

WILLIS, Texas, Oct. 12, 2026 /PRNewswire/ -- Author Katie Guilbault has released "Refine: An Anthology of Learning Life's Lessons the Hard Way," a collection of poetry and prose that explores grief, healing, motherhood, love, faith, mental health and self-discovery through reflections inspired by her personal experiences. In the book, Guilbault examines how life's greatest challenges can shape personal growth while encouraging readers to reflect on their own experiences with loss, resilience and transformation.

Organized as a series of poems and reflective essays, "Refine" follows Guilbault through childhood memories, changing family dynamics, motherhood, relationships and personal struggles. The collection addresses topics including mental health, generational trauma, divorce, body image, forgiveness and hope while documenting the experiences that have shaped her perspective over time.

"My goal is to give language to the parts of healing that people often experience in silence," Guilbault said. "I hope readers see pieces of their own story reflected and feel encouraged to continue refining who they are becoming."

Rather than presenting healing as a destination, Guilbault portrays it as an ongoing process marked by setbacks, reflection and personal growth. Each poem and prose piece builds on the last, creating a narrative that follows the author's journey from heartbreak and uncertainty to renewed purpose and hope. The collection encourages readers to reflect on their own lives while considering how even difficult experiences can become sources of wisdom and transformation.

"Healing is not linear, and every difficult season has shaped who I am today," Guilbault said. "I want readers to know that honest self-examination is necessary for transformation."

"Refine: An Anthology Of Learning Life's Lessons The Hard Way"

By Katie Guilbault

ISBN: 9798765268421 (softcover); 9798765268414 (hardcover); 9798765268407 (electronic)

Available on BalboaPress, Amazon and Barnes & Noble 

About the author

Katie Guilbault is a dreamer, a fighter, a mother and a writer. Drawing inspiration from surviving life with tomfoolery and therapeutic poetry. She is deeply spiritual and attributes her work to her purpose in life; creating community. To learn more, please visit https://www.balboapress.com/en/bookstore/bookdetails/872089-refine.

General Inquiries:

LAVIDGE – Phoenix

Maeve Larson

[email protected]

SOURCE Balboa Press

Share this article

Noble Corporation plc to announce third quarter 2026 results

HOUSTON, Oct. 12, 2026 /PRNewswire/ -- Noble Corporation plc ("Noble" or the "Company") (NYSE: NE) today announces plans to report financial results for the third quarter on Monday, October 26, 2026. The Company's earnings press release and accompanying earnings presentation will be available on Noble's website at www.noblecorp.com.

Noble will host a conference call related to its third quarter 2026 results on Tuesday, October 27, 2026, at 8:00 a.m. U.S. Central Time. Interested parties may dial (800) 715-9871 and refer to conference ID 4018911 approximately 15 minutes prior to the scheduled start time. A live webcast link will be available on the Investor Relations section of the Company's website, and a webcast replay will be accessible for a limited time following the scheduled call.

About Noble Corporation

Noble is a leading offshore drilling contractor for the oil and gas industry. The Company owns and operates one of the most modern, versatile, and technically advanced fleets in the offshore drilling industry. Noble and its predecessors have been engaged in the contract drilling of oil and gas wells since 1921. Noble performs, through its subsidiaries, contract drilling services with a fleet of offshore drilling units focused largely on ultra-deepwater and high specification jackup drilling opportunities in both established and emerging regions worldwide. For further information, visit www.noblecorp.com or email [email protected].

SOURCE Noble Corporation plc

Share this article

HOUSTON, Oct. 12, 2026 /PRNewswire/ -- Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) today announced the Company's schedule for releasing its third quarter 2026 financial and operating results.

The Company plans to issue its third quarter 2026 financial and operating results press release after market close on Tuesday, November 3, 2026, and host its earnings conference call on Wednesday, November 4, 2026, at 9:00 a.m. CT (10:00 a.m. ET). The press release will be posted on the Company's website at https://ir.flotekind.com/press-releases.

Participants may access the call through Flotek's website at https://ir.flotekind.com/events, by telephone toll free at 1-800-836-8184 (international toll: 1-646-357-8785), or by using the following link to access the webcast: https://app.webinar.net/KaD61d81pgX approximately five minutes prior to the start of the call. Following the conclusion of the conference call, a recording of the call will be available on the Company's website.

About Flotek Industries, Inc.

Flotek Industries, Inc. is a global technology-driven company that combines the synergy of proprietary technologies through near real-time data analytics and advanced chemistry to collaboratively address complex challenges for energy, industrial and infrastructure sector customers and help them optimize operations, enhance asset performance and maximize financial returns.

Leveraging a portfolio of more than 130 patents, over two decades of field and laboratory data, and a global presence in more than 59 countries, Flotek delivers innovative, data-driven solutions designed to create measurable value across the energy and infrastructure lifecycle.

Flotek is based in Houston, Texas and its common shares are traded on the New York Stock Exchange under the ticker symbol "FTK." For additional information, please visit www.flotekind.com.

SOURCE Flotek Industries, Inc.

Share this article

Match Group to Announce Third Quarter 2026 Results

LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Match Group (NASDAQ: MTCH) will release financial results and full prepared remarks for the third quarter 2026 on Monday, November 2, 2026 after-market close. The company will host its quarterly conference call on the same day at 5:00 p.m. ET with brief remarks followed by a question and answer session.

A live webcast of the conference call, along with supplemental investor materials, can be accessed at https://ir.mtch.com. A replay of the webcast will be available through the same link following the conference call.

About Match Group

Match Group is leading the next chapter of human connection. Our global portfolio of brands — including Tinder, Hinge, Azar, Match, Pairs, BLK, Upward, OurTime, The League, HER, and more — spark meaningful real-world connections across cultures, communities, and every stage of life. Learn more at https://mtch.com/.

SOURCE Match Group

Share this article

LINCOLN, Neb., Oct. 12, 2026 /PRNewswire/ -- Nelnet, Inc. (NYSE: NNI) today announced it will release earnings for the third quarter ended September 30, 2026, after the close of the New York Stock Exchange on Thursday, November 5, 2026. Upon release, additional earnings information will be available at www.nelnetinvestors.com.

Learn more about Nelnet at www.nelnet.com.

SOURCE Nelnet, Inc.

Share this article

MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ -- Meta Platforms, Inc. (NASDAQ: META) announced today that the company's third quarter 2026 financial results will be released after market close on Wednesday, October 21st, 2026.

Meta will host a conference call to discuss its results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the call can be accessed at the Meta Investor Relations website at investor.atmeta.com, along with the company's earnings press release, financial tables, and slide presentation.

Following the call, a replay will be available at the same website. Transcripts of conference calls with publishing equity research analysts held on October 21st, 2026 will also be posted to the investor.atmeta.com website.

Disclosure Information 

Meta uses the investor.atmeta.com and meta.com/news websites as well as Mark Zuckerberg's Facebook profile (facebook.com/zuck), Instagram account (instagram.com/zuck) and Threads profile (threads.net/zuck) as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Meta

Meta is building the future of human connection, powered by artificial intelligence and immersive technologies. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram, and WhatsApp further empowered billions around the world. Now, Meta is moving toward building experiences that foster deeper connections and unlock new possibilities.

Contacts

Investors:

Rob Bevegni

[email protected] /  investor.atmeta.com 

Press:

Matt Tye

[email protected] / meta.com/news

SOURCE Meta

Share this article

The article clarifies how real ceramic tint differs from standard films and why performance matters in high-heat environments.

SAN ANTONIO, Oct. 12, 2026 /PRNewswire/ -- What should drivers in South Texas look for when choosing a window tint that truly performs in extreme heat? A new HelloNation article provides clear answers by explaining how to distinguish between standard products and genuine ceramic film.

In the feature, Marco Escamilla and Hilary Escamilla of Platinum Auto Films in San Antonio walk readers through the science behind true ceramic window tint. The article explains how this type of non-metallic window film works and why it performs better in high-temperature environments, such as those in South Texas. Unlike dyed or metallic films, real ceramic film uses advanced ceramic particles to block heat and UV without compromising clarity or color, and without interfering with onboard electronics.

The Escamillas clarify a growing issue in the industry: not all films labeled "ceramic" deliver the performance consumers expect. For those researching ceramic tint vs regular tint, the article notes that the difference often lies in how the film behaves over time. Regular tints may look similar at first but tend to fade, bubble, or lose heat-rejecting ability within a few years. By contrast, real ceramic film remains stable and efficient, offering long-term value.

This long-term performance is critical in hot climates. The article details how true ceramic window tint in San Antonio delivers measurable heat rejection, keeping car interiors cooler while preserving the condition of dashboards and seats. For San Antonio drivers, that means more than just comfort—it's protection for their vehicle's electronics and materials, which are exposed to UV damage day after day.

According to the HelloNation feature, one of the most telling signs of real ceramic film is its ability to maintain both its appearance and performance over time. Unlike dyed tints, which may turn purple, or metallic tints that block GPS or phone signals, true ceramic tint remains color-stable and allows seamless digital connectivity. The Escamillas encourage car owners to verify product specifications and look for performance data that supports claims about window tint heat rejection and UV filtering.

Another benefit covered in the article is the durability of non-metallic window film. The chemical structure of ceramic particles enables the film to resist sunlight degradation, resulting in fewer replacements and longer-lasting protection. This contributes to the overall benefits of ceramic window tint that many vehicle owners don't realize until after they've had a subpar product installed.

Drivers are advised to ask questions about warranty terms, infrared rejection levels, and manufacturer details before selecting a tint. The article suggests that informed decisions come from understanding how the tint works, not just what it is called. For anyone comparing ceramic tint vs. regular tint, the differences may seem small at first, but the impact becomes obvious under daily sun exposure.

As described in the feature, true ceramic window tint in San Antonio is more than a cosmetic upgrade. It's a long-term solution for comfort, protection, and performance. The Escamillas' advice encourages buyers to be cautious of vague labeling and to look for products backed by transparent testing and technical data.

The article titled "What Makes True Ceramic Tint Different" features insights from Marco Escamilla and Hilary Escamilla, Auto Tinting Experts in San Antonio, TX, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the "Class Period"), of the important November 10, 2026 lead plaintiff deadline.

So What: If you purchased Lincoln Educational Services securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Lincoln Educational Services class action, go to https://rosenlegal.com/cases/lincoln-educational-services-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Lincoln Educational Services' admissions process was not effectively converting students from enrollment to start; (2) as a result, Lincoln Educational Services was experiencing a significant drop in student starts relative to enrollment; and (3) as a result of the foregoing, defendants' positive statements about Lincoln Educational Services' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lincoln Educational Services class action, go to https://rosenlegal.com/cases/lincoln-educational-services-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article